Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tectonic Therapeutic, Inc. (TECX : NSDQ)
 
 • Company Description   
Tectonic Therapeutic Inc. is a biotechnology company developing GPCR -targeted therapeutic proteins. Tectonic Therapeutic Inc., formerly known as AVROBIO Inc., is based in CAMBRIDGE, Mass.

Number of Employees: 60

 
 • Price / Volume Information   
Yesterday's Closing Price: $29.12 Daily Weekly Monthly
20 Day Moving Average: 233,828 shares
Shares Outstanding: 18.87 (millions)
Market Capitalization: $549.47 (millions)
Beta: 3.27
52 Week High: $36.03
52 Week Low: $14.39
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.39% -2.61%
12 Week 21.69% 12.50%
Year To Date 39.60% 25.70%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
490 ARSENAL WAY SUITE 200
-
WATERTOWN,MA 02472
USA
ph: 339-666-3320
fax: -
daniel@lifesciadvisors.com http://www.tectonictx.com
 
 • General Corporate Information   
Officers
Alise Reicin - President; Chief Executive Officer and Director
Daniel Lochner - Chief Financial Officer
Terrance McGuire - Director
Stefan Vitorovic - Director
Timothy A. Springer - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 878972108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/06/26
Share - Related Items
Shares Outstanding: 18.87
Most Recent Split Date: (:1)
Beta: 3.27
Market Capitalization: $549.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.33 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-5.33 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.38
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -44.09%
vs. Previous Quarter: -30.10%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/26 - -32.33
12/31/25 - -26.88
09/30/25 - -27.11
ROA
03/31/26 - -30.92
12/31/25 - -25.83
09/30/25 - -25.88
Current Ratio
03/31/26 - 18.51
12/31/25 - 26.62
09/30/25 - 29.15
Quick Ratio
03/31/26 - 18.51
12/31/25 - 26.63
09/30/25 - 29.15
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Book Value
03/31/26 - 12.21
12/31/25 - 13.43
09/30/25 - 14.30
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.01
12/31/25 - 0.02
09/30/25 - 0.04
 

Powered by Zacks Investment Research ©